MC4R and metabolic dysfunction-associated steatohepatitis: When administered to MC4R-KO mice, βCD-PRX effectively ameliorated liver fibrosis at least partly by decreasing free cholesterol content in macrophages and suppressing the activation of profibrotic pathways in a NASH model, without affecting the hepatic and serum levels of cholesterol.